Jiajin Bio is a pharmaceutical R&D service provider. The company focuses on the research and development of antibody-small nucleic acid conjugates. Recently, Jiajin Bio has successfully completed an angel round of financing of tens of millions of RMB, which was jointly led by Matrix Partners and Fengrui Capital. The funds obtained are used for pipeline research and development, patent layout, company operations including laboratory platform construction, etc.
This article is reproduced from: https://www.itjuzi.com/investevent/13358592
This site is for inclusion only, and the copyright belongs to the original author.